Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
- DOI
- 10.1002/ijc.34912
- Published
- 2024 Jul 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.34912,
title = {Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.},
author = {Lüftner D and Schuetz F and Schneeweiss A and Hartkopf A and Bloch W and Decker T and Uleer C and Stötzer O and Foerster F and Schmidt M and Mundhenke C and Tesch H and Jackisch C and Fischer T and Kreuzeder J and Guderian G and Fasching PA},
year = {2024},
journal = {International journal of cancer},
doi = {10.1002/ijc.34912},
url = {https://doi.org/10.1002/ijc.34912}
}RIS
TY - JOUR TI - Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. AU - Lüftner D AU - Schuetz F AU - Schneeweiss A AU - Hartkopf A AU - Bloch W AU - Decker T AU - Uleer C AU - Stötzer O AU - Foerster F AU - Schmidt M AU - Mundhenke C AU - Tesch H AU - Jackisch C AU - Fischer T AU - Kreuzeder J AU - Guderian G AU - Fasching PA PY - 2024 JO - International journal of cancer DO - 10.1002/ijc.34912 UR - https://doi.org/10.1002/ijc.34912 ER -
APA
D, L., F, S., A, S., A, H., W, B., T, D., C, U., O, S., F, F., M, S., C, M., H, T., C, J., T, F., J, K., G, G., & PA, F. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.. International journal of cancer. https://doi.org/10.1002/ijc.34912
Source records
- pubmed · retrieved 2026-09-26T18:33:37.242Z